FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283014034> ?p ?o ?g. }

• W4283014034 endingPage "e004841" @default.
• W4283014034 startingPage "e004841" @default.
• W4283014034 abstract "Background Human epidermal growth factor receptor 2 (HER2) targeted antibodies in combination with chemotherapy has improved outcomes of HER2 positive (pos) breast cancer (BC) but toxicity of therapy remains a problem. High levels of tumor-infiltrating lymphocytes are associated with increased pathologic complete responses for patients treated with neoadjuvant therapy. Here we sought to investigate whether delivery of intratumoral (i.t.) multiepitope major histocompatibility complex (MHC) class II HER2 peptides-pulsed type I polarized dendritic cells (HER2-DC1) in combination with anti-HER2 antibodies without chemotherapy could enhance tumor regression by increasing anti-HER2 lymphocyte infiltration into the tumor. Methods BALB/c mice bearing orthotopic TUBO tumors, BALB/c mice bearing subcutaneous (s.c.) CT26 hHER2 tumors, or BALB-HER2/neu transgenic mice were all treated with i.t. or s.c. HER2-DC1, anti-HER2 antibodies, paclitaxel, T-DM1 or in combination. Immune response, host immune cells and effector function were analyzed using flow cytometry, interferon-γ ELISA and cytokine/chemokine arrays. The contributions of CD4 + and CD8 + T cells and antibody dependent cellular cytotoxicity (ADCC) were assessed using depleting antibodies and FcγR KO mice. Molecular changes were evaluated by immunohistochemistry and western blot. Results HER2-DC1 combined with anti-HER2 antibodies delivered i.t. compared to s.c. induced complete tumor regression in 75–80% of treated mice, with increased tumor infiltrating CD4 + and CD8 + T, B, natural killer T cells (NKT) and natural killer cells, and strong anti-HER2 responses in all HER2 pos BC models tested. The therapy caused regression of untreated distant tumors. Labeled HER2-DC1 migrated prominently into the distant tumor and induced infiltration of various DC subsets into tumors. HER2-DC1 i.t. combined with anti-HER2 antibodies displayed superior antitumor response compared to standard chemotherapy with anti-HER2 antibodies. Lasting immunity was attained which prevented secondary tumor formation. The presence of CD4 + and CD8 + T cells and ADCC were required for complete tumor regression. In the HER2 pos BC models, HER2-DC1 i.t. combined with anti-HER2 antibodies effectively diminished activation of HER2-mediated oncogenic signaling pathways. Conclusions HER2-DC1 i.t. with anti-HER2 antibodies mediates tumor regression through combined activation of T and B cell compartments and provides evidence that HER2-DC1 i.t. in combination with anti-HER2 antibodies can be tested as an effective alternative therapeutic strategy to current chemotherapy and anti-HER2 antibodies in HER2 pos BC." @default.
• W4283014034 created "2022-06-18" @default.
• W4283014034 creator A5006005284 @default.
• W4283014034 creator A5033136543 @default.
• W4283014034 creator A5033713736 @default.
• W4283014034 creator A5042586488 @default.
• W4283014034 creator A5051624923 @default.
• W4283014034 creator A5051916408 @default.
• W4283014034 creator A5053032439 @default.
• W4283014034 creator A5054578914 @default.
• W4283014034 creator A5055889746 @default.
• W4283014034 creator A5059240684 @default.
• W4283014034 creator A5061549831 @default.
• W4283014034 creator A5062615352 @default.
• W4283014034 creator A5072295287 @default.
• W4283014034 date "2022-06-01" @default.
• W4283014034 modified "2023-09-26" @default.
• W4283014034 title "Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma" @default.
• W4283014034 cites W1530219086 @default.
• W4283014034 cites W1795586350 @default.
• W4283014034 cites W1969312124 @default.
• W4283014034 cites W1986825880 @default.
• W4283014034 cites W2009043731 @default.
• W4283014034 cites W2015512041 @default.
• W4283014034 cites W2066477716 @default.
• W4283014034 cites W2088539087 @default.
• W4283014034 cites W2092982811 @default.
• W4283014034 cites W2095633632 @default.
• W4283014034 cites W2095861620 @default.
• W4283014034 cites W2097960989 @default.
• W4283014034 cites W2131748930 @default.
• W4283014034 cites W2138249160 @default.
• W4283014034 cites W2142845582 @default.
• W4283014034 cites W2144405588 @default.
• W4283014034 cites W2147746178 @default.
• W4283014034 cites W2153086428 @default.
• W4283014034 cites W2169344919 @default.
• W4283014034 cites W2259054892 @default.
• W4283014034 cites W2335057960 @default.
• W4283014034 cites W2379981061 @default.
• W4283014034 cites W2460150844 @default.
• W4283014034 cites W2465531059 @default.
• W4283014034 cites W2559858344 @default.
• W4283014034 cites W2560406314 @default.
• W4283014034 cites W2565834876 @default.
• W4283014034 cites W2565898883 @default.
• W4283014034 cites W2611671407 @default.
• W4283014034 cites W2624590002 @default.
• W4283014034 cites W2745792339 @default.
• W4283014034 cites W2770219561 @default.
• W4283014034 cites W2774455292 @default.
• W4283014034 cites W2800084163 @default.
• W4283014034 cites W2801385868 @default.
• W4283014034 cites W2900046418 @default.
• W4283014034 cites W2902218997 @default.
• W4283014034 cites W2908820507 @default.
• W4283014034 cites W2918171974 @default.
• W4283014034 cites W2938889495 @default.
• W4283014034 cites W2942790586 @default.
• W4283014034 cites W2948553535 @default.
• W4283014034 cites W2948835056 @default.
• W4283014034 cites W2965352578 @default.
• W4283014034 cites W2970536272 @default.
• W4283014034 cites W2994610571 @default.
• W4283014034 cites W2996630100 @default.
• W4283014034 cites W3010163295 @default.
• W4283014034 cites W3012380787 @default.
• W4283014034 cites W3048641542 @default.
• W4283014034 cites W3097463205 @default.
• W4283014034 cites W3120311604 @default.
• W4283014034 cites W3131151008 @default.
• W4283014034 cites W3138780880 @default.
• W4283014034 cites W3158086066 @default.
• W4283014034 cites W3164445007 @default.
• W4283014034 cites W3165177412 @default.
• W4283014034 cites W3176649308 @default.
• W4283014034 cites W3188251561 @default.
• W4283014034 cites W4226229111 @default.
• W4283014034 cites W4237052860 @default.
• W4283014034 doi "https://doi.org/10.1136/jitc-2022-004841" @default.
• W4283014034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35710296" @default.
• W4283014034 hasPublicationYear "2022" @default.
• W4283014034 type Work @default.
• W4283014034 citedByCount "2" @default.
• W4283014034 countsByYear W42830140342022 @default.
• W4283014034 countsByYear W42830140342023 @default.
• W4283014034 crossrefType "journal-article" @default.
• W4283014034 hasAuthorship W4283014034A5006005284 @default.
• W4283014034 hasAuthorship W4283014034A5033136543 @default.
• W4283014034 hasAuthorship W4283014034A5033713736 @default.
• W4283014034 hasAuthorship W4283014034A5042586488 @default.
• W4283014034 hasAuthorship W4283014034A5051624923 @default.
• W4283014034 hasAuthorship W4283014034A5051916408 @default.
• W4283014034 hasAuthorship W4283014034A5053032439 @default.
• W4283014034 hasAuthorship W4283014034A5054578914 @default.
• W4283014034 hasAuthorship W4283014034A5055889746 @default.
• W4283014034 hasAuthorship W4283014034A5059240684 @default.
• W4283014034 hasAuthorship W4283014034A5061549831 @default.

• next